Beyond belatacept: Praise and progress for the FDA

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 513-514

  Vincenti, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CYCLOSPORIN A;

ACUTE GRAFT REJECTION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

CONSUMER PRODUCT SAFETY; DRUG APPROVAL; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84857652030     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03975.x     Document Type: Editorial

References (11)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B,. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383. (Pubitemid 38282293)
2. Lamb KE, Lodhi S, Meier-Kriesche HU,. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450-462.
3. Boggs J,. Autoimmune, CNS diseases: Top-dollar antibodies deals. BioWorld Today November 11 2011; 22: 1.
4. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J,. Summary of the US FDA approval of belatacept. Am J Transplant 2012; 12: 554-562.
5. Sellarés J, de Freitas DG, Mengel M, et al,. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011; 11: 489-499.
6. Everly MJ, Everly JJ, Arend LJ, et al,. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063-1071.
7. Vincenti F, Larsen CP, Alberu J, et al,. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
8. Pestana JO, Grinyo JM, Vanrenterghem Y, et al,. Three-year outcome from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; doi
9. Ojo AO, Held PJ, Port FK, et al,. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)
10. Powles AV, Cook T, Hulma B, et al,. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporine for psoriasis. Br J Dermatol 1993; 128: 159-165. (Pubitemid 23054333)
11. Tostivint I, du Montel SF, Jaudon MC, et al,. Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 2007; 22: 880-885. (Pubitemid 46351700)